Pharmacotherapy in the management of early Parkinson’s disease: cost-effectiveness and patient acceptability

References

• KuopioAMMarttilaRJHeleniusHToivonenMRinneUKThe quality of life in Parkinson’s diseaseMov Disord200015221622310752569
   PubMed Web of Science ®Google Scholar
• CarterJHStewartPGArchboldPGLiving with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Parkinson’s study groupMov Disord199813120289452321
   PubMed Web of Science ®Google Scholar
• KeränenTKaakkolaSSotaniemiKEconomic burden and quality of life impairment increase with severity of PDParkinsonism Relat Disord20039316316812573872
   PubMed Web of Science ®Google Scholar
• JancaAParkinson’s disease from WHO perspective and a public health point of viewParkinsonism Relat Disord2002913612217616
   PubMed Web of Science ®Google Scholar
• GuttmanMSlaughterPMTheriaultMEDeBoerDPNaylorCDBurden of parkinsonism: a population-based studyMov Disord200318331331612621635
   PubMed Web of Science ®Google Scholar
• WelshMParkinson’s disease and quality of life: issues and challenges beyond motor symptomsNeurol Clin200422Suppl 3S141S14815501362
   PubMed Web of Science ®Google Scholar
• DodelRCSingerMKohne-VollandRThe economic impact of Parkinson’s diseasePharmacoeconomics199814329931210186468
   PubMed Web of Science ®Google Scholar
• EisenbergJMClinical economics. A guide to economic analysis of clinical practicesJAMA198926220287928862509745
   PubMed Web of Science ®Google Scholar
• MarkhamCHDiamondSGLong-term follow-up of early dopa treatment in Parkinson’s diseaseAnn Neurol19861943653723707088
   PubMed Web of Science ®Google Scholar
• MarsdenCDProblems with long-term levodopa therapy for Parkinson’s diseaseClin Neuropharmacol199417Suppl 2S32S449358193
   PubMed Web of Science ®Google Scholar
• ClarkeCENeuroprotection and pharmacotherapy for motor symptoms in Parkinson’s diseaseLancet Neurol20043846647415261607
   PubMed Web of Science ®Google Scholar
• HoehnMMYahrMDParkinsonism: onset, progression and mortalityNeurology19671754274426067254
   PubMed Web of Science ®Google Scholar
• EggertKMReeseJPOertelWHDodelRCost effectiveness of pharmacotherapies in early Parkinson’s diseaseCNS Drugs2008221084186018788836
   PubMed Web of Science ®Google Scholar
• FahnRECommitteeUDUnified Parkinson’s Disease Rating ScaleFahnSCalneDGoldsteinMRecent Developments in Parkinson’s diseaseFlorham ParkMacmillan Healthcare information1987153163
   Google Scholar
• GoetzCGTilleyBCShaftmanSRMovement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing resultsMov Disord200823152129217019025984
   PubMed Web of Science ®Google Scholar
• KarlsenKHTandbergEArslandDLarsenJPHealth related quality of life in Parkinson’s disease: a prospective longitudinal studyJ Neurol Neurosurg Psychiatry200069558458911032608
   PubMed Web of Science ®Google Scholar
• Martinez-MartinPArroyoSRojo-AbuinJMBurden, perceived health status, and mood among caregivers of Parkinson’s disease patientsMov Disord200823121673168018709684
   PubMed Web of Science ®Google Scholar
• HagellPWhalleyDMcKennaSPLindvallOHealth status measurement in Parkinson’s disease: validity of the PDQ-39 and Nottingham Health ProfileMov Disord200318777378312815656
   PubMed Web of Science ®Google Scholar
• Martínez-MartínPGrandasFLinazasoroGBravoJLConversion to controlled-release levodopa/carbidopa treatment and quality of life as measured by the Nottingham Health Profile. The STAR Study GroupNeurologia199914733834310570620
   PubMedGoogle Scholar
• BrazierJEHarperRJonesNMValidating the SF-36 health survey questionnaire: new outcome measure for primary careBMJ199230568461601641285753
   PubMed Web of Science ®Google Scholar
• LongstrethWTJrNelsonLLindeMMuñozDUtility of the sickness impact profile in Parkinson’s diseaseJ Geriatr Psychiatry Neurol1992531421481497791
   PubMedGoogle Scholar
• The EuroQoL GroupEuroQol – a new facility for the measurement of health-related quality of life. The EuroQol GroupHealth Policy199016319920810109801
   PubMed Web of Science ®Google Scholar
• SiderowfARavinaBGlickHAPreference-based quality-of-life in patients with Parkinson’s diseaseNeurology200259110310812105315
   PubMed Web of Science ®Google Scholar
• PetoVJenkinsonCFitzpatrickRPDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measuresJ Neurol1998245Suppl 1S10S149617716
   PubMed Web of Science ®Google Scholar
• PetoVJenkinsonCFitzpatrickRGreenhallRThe development and validation of a short measure of functioning and well being for individuals with Parkinson’s diseaseQual Life Res1995432412487613534
   PubMed Web of Science ®Google Scholar
• de BoerAGWijkerWSpeelmanJDde HaesJCQuality of life in patients with Parkinson’s disease: development of a questionnaireJ Neurol Neurosurg Psychiatry199661170748676165
   PubMed Web of Science ®Google Scholar
• WelshMMcDermottMPHollowayRGDevelopment and testing of the Parkinson’s disease quality of life scaleMov Disord200318663764512784266
   PubMed Web of Science ®Google Scholar
• SchulzerMMakECalneSMThe psychometric properties of the Parkinson’s Impact Scale (PIMS) as a measure of quality of life in Parkinson’s diseaseParkinsonism Relat Disord20039529129412781596
   PubMed Web of Science ®Google Scholar
• McCronePAllcockLMBurnDJPredicting the cost of Parkinson’s diseaseMov Disord200722680481217290462
   PubMed Web of Science ®Google Scholar
• DodelRCEggertKMSingerMSEichhornTEPogarellOOertelWHCosts of drug treatment in Parkinson’s diseaseMov Disord19981322492549539337
   PubMed Web of Science ®Google Scholar
• CuboEMartínez MartinPGonzálezMFradesBmiembros del grupo ELEPImpact of motor and non-motor symptoms on the direct costs of Parkinson’s diseaseNeurologia2009241152319003550
   PubMed Web of Science ®Google Scholar
• LeibsonCLLongKHMaraganoreDMDirect medical costs associated with Parkinson’s disease: a population-based studyMov Disord200621111864187116977632
   PubMed Web of Science ®Google Scholar
• SiderowfADHollowayRGSternMBCost-effectiveness analysis in Parkinson’s disease: determining the value of interventionsMov Disord200015343944510830407
   PubMed Web of Science ®Google Scholar
• CoyleDBarbeauMGuttmanMBaladiJFThe economic evaluation of pharmacotherapies for Parkinson’s diseaseParkinsonism Relat Disord20039530130712781598
   PubMed Web of Science ®Google Scholar
• MearaJBhowmickBKHobsonPAccuracy of diagnosis in patients with presumed Parkinson’s diseaseAge Ageing19992829910210350403
   PubMed Web of Science ®Google Scholar
• ScherflerCSchwarzJAntoniniARole of DAT-SPECT in the diagnostic work up of parkinsonismMov Disord20072291229123817486648
   PubMed Web of Science ®Google Scholar
• AntoniniABertoPLopatrielloSTammaFAnnemansLChambersMCost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson’s disease in ItalyMov Disord200823152202220918785639
   PubMed Web of Science ®Google Scholar
• StoesslAJRadionuclide scanning to diagnose Parkinson disease: is it cost-effective?Nat Clin Pract Neurol200951101119065134
   PubMedGoogle Scholar
• AsimakopoulosPCaslakeRHarrisCEGordonJCTaylorKSCounsellCChanges in quality of life in people with Parkinson’s disease left untreated at diagnosisJ Neurol Neurosurg Psychiatry200879671671818223017
   PubMed Web of Science ®Google Scholar
• VossiusCNilsenOBLarsenJPHealth state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort studyDrugs Aging2009261197398019848442
   PubMed Web of Science ®Google Scholar
• LeesAAlternatives to levodopa in the initial treatment of early Parkinson’s diseaseDrugs Aging200522973174016156677
   PubMed Web of Science ®Google Scholar
• BrysonHMMilneRJChrispPSelegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson’s diseasePharmacoeconomics19922211813610146952
   PubMedGoogle Scholar
• HaycoxAArmandCMurteiraSCochranJFrançoisCCost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting: an economic Markov model evaluationDrugs Aging200926979180119728752
   PubMed Web of Science ®Google Scholar
• BiglanKMSchwidSEberlySRasagiline improves quality of life in patients with early Parkinson’s diseaseMov Disord200621561662316450340
   PubMed Web of Science ®Google Scholar
• BiglanKMHollowayRGA review of pramipexole and its clinical utility in Parkinson’s diseaseExpert Opin Pharmacother20023219721011829733
   PubMedGoogle Scholar
• HoergerTJBalaMVRowlandCGreerMChrischillesEAHollowayRGCost effectiveness of pramipexole in Parkinson’s disease in the USPharmacoeconomics199814554155710344917
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGfor Parkinson Study GroupPramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trialMed Decis Making200424547248515358996
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGfor Parkinson Study GroupPramipexole and levodopa in early Parkinson’s disease: dynamic changes in cost effectivenessPharmacoeconomics200523121257127016336019
   PubMed Web of Science ®Google Scholar
• NoyesKDickAWHollowayRGThe implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluationMed Decis Making200727332733417502449
   PubMed Web of Science ®Google Scholar
• IskedjianMEinarsonTRCost analysis of ropinirole versus levodopa in the treatment of Parkinson’s diseasePharmacoeconomics200321211512712515573
   PubMed Web of Science ®Google Scholar
• van der MarckMAKalfJGSturkenboomIHNijkrakeMJMunnekeMBloemBRMultidisciplinary care for patients with Parkinson’s diseaseParkinsonism Relat Disord200915Suppl 3S219S22320082995
   PubMed Web of Science ®Google Scholar
• KeussSHJHendriksHJMBloemBRKNGF Guidelines for physical therapy in Parkinson’s diseaseNed Tijdschr Fysiother20041143 Suppl. Available at: www.knfg.nl or www.cehp.nl (cited 2008 Mar 10).
   Google Scholar
• MunnekeMNijkrakeMJKeusSHEfficacy of community-based physiotherapy networks for patients with Parkinson’s disease: a cluster-randomised trialLancet Neurol20109465419959398
   PubMed Web of Science ®Google Scholar
• Brefel-CourbonCDesboeufKThalamasCClinical and economic analysis of spa therapy in Parkinson’s diseaseMov Disord200318557858412722173
   PubMed Web of Science ®Google Scholar
• GageHKayeJOwenCTrendPWadeDEvaluating rehabilitation using cost-consequences analysis: an example in Parkinson’s diseaseClin Rehabil200620323223816634342
   PubMed Web of Science ®Google Scholar
• AbbottRDRossGWWhiteLRExcessive daytime sleepiness and subsequent development of Parkinson’s diseaseNeurology2005651442144616275833
   PubMed Web of Science ®Google Scholar